**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 87029

**Manuscript Type:** REVIEW

**New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage**

Reshetnyak VI *et al*. PBC asymptomatic stage pathogenesis

Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev

**Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev,** Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow 127473, Russia

**Author contributions:** Reshetnyak VI and Maev IV have equally contributed to the study conception and design, literature review and analysis, drafting, critical revision and editing, and approval of the final version.

**Corresponding author: Vasiliy Ivanovich Reshetnyak, DSc, MD, PhD, Full Professor,** Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, No. 20 Delegatskaya St, Moscow 127473, Russia. vasiliy.reshetnyak@yandex.ru

**Received:** July 19, 2023

**Revised:** August 10, 2023

**Accepted:** September 14, 2023

**Published online:**

**Abstract**

Primary biliary cholangitis (PBC) is a chronic cholestatic progressive liver disease and one of the most important progressive cholangiopathies in adults. Damage to cholangiocytes triggers the development of intrahepatic cholestasis, which progresses to cirrhosis in the terminal stage of the disease. Accumulating data indicate that damage to biliary epithelial cells [(BECs), cholangiocytes] is most likely associated with the intracellular accumulation of bile acids, which have potent detergent properties and damaging effects on cell membranes. The mechanisms underlying uncontrolled bile acid intake into BECs in PBC are associated with pH change in the bile duct lumen, which is controlled by the bicarbonate (HCO3-) buffer system “biliary HCO3- umbrella”. The impaired production and entry of HCO3- from BECs into the bile duct lumen is due to epigenetic changes in expression of the X-linked microRNA 506. Based on the growing body of knowledge on the molecular mechanisms of cholangiocyte damage in patients with PBC, we propose a hypothesis explaining the pathogenesis of the first morphologic (ductulopenia), immunologic (antimitochondrial autoantibodies) and clinical (weakness, malaise, rapid fatigue) signs of the disease in the asymptomatic stage. This review focuses on the consideration of these mechanisms.

**Key Words:** Primary biliary cholangitis; Antimitochondrial autoantibodies; MicroRNA 506; Inositol-1,4,5-trisphosphate receptor type 3; Chloride/bicarbonate anion exchanger 2; Biliary bicarbonate umbrella; Dihydrolipoyl transacetylase (E2 subunit); Pyruvate dehydrogenase complex

Reshetnyak VI, Maev IV. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage. *World J Gastroenterol* 2023; In press

**Core Tip:** This review considers the mechanisms contributing to the damage of the E2 subunit of the pyruvate dehydrogenase complex, formation of antimitochondrial autoantibodies (AMAs), and the development of ductulopenia in primary biliary cholangitis asymptomatic stage. A hypothesis explaining the pathogenesis of the initial morphological (ductulopenia), immunologic (AMAs), and clinical (weakness, malaise, rapid fatigue) signs of the disease in the asymptomatic stage is proposed.

**INTRODUCTION**

Primary biliary cholangitis (PBC) is a chronic cholestatic progressive liver disease of autoimmune etiology, characterized by the destruction, necrosis, and apoptosis of small bile duct epithelial cells, in the terminal stage of which cirrhosis develops[1-3]. PBC development is preceded by a long asymptomatic period[1,2], during which time there are no physical signs of the disease. The earliest and most common symptoms are fatigue, weakness, and malaise. Detection of serum antimitochondrial autoantibodies (AMAs) at a titer ≥ 1: 40 during this period serves as a pathognomonic marker of PBC development. AMAs are detectable months to years before PBC manifests clinically, indicating their primary immunopathogenetic role rather than a secondary phenomenon occurring as a consequence of cholestasis[4,5]. However, AMAs titer does not correlate with disease activity or duration[4-7]. Identifying the causes and mechanisms of AMAs formation may contribute to understanding the pathogenesis of the development of clinical, morphologic, biochemical, and immunologic signs of PBC.

AMAs are not strictly specific for PBC[4]. They are classified as immunoglobulin (Ig) M which reacts with multiple antigens in mitochondria, designated M1-M9[8]. The highly sensitive and most frequent (> 95%) AMAs found in PBC are anti-M2 IgM[8]. In patients with classical PBC, the antigenic components of AMAs are related to the dihydrolipoyl transacetylase (E2 subunit) of the pyruvate dehydrogenase (PDC) complex (E2 PDC), which localizes to the inner mitochondrial membrane[8]. Immunization of laboratory animals with E2 PDC recombinant polypeptide leads to AMAs formation but not cholangiocyte damage[9], indicating that AMAs do not trigger the destruction of biliary epithelial cells [(BECs), cholangiocytes].

It is critical to understand how the E2 PDC antigen of BECs, located on the inner membrane of mitochondria in small and medium-sized bile ducts, can be a target of immune effector mechanisms[4]. The theory of antigenic mimicry is discussed below.

**AMAs AND THE THEORY OF ANTIGENIC MIMICRY**

The PDC in prokaryotes is structurally similar to that of eukaryotes[10]. Antibodies from the serum of patients with PBC have been shown to react with yeast and bacterial proteins[11,12]. Therefore, it has been suggested that AMAs in PBC arise due to cross-reactivity to exogenous bacterial antigens (antigenic mimicry)[13,14] and that the disease may have a bacterial origin[15]. However, there is no clear evidence of an infectious agent[4]. In classic bacterial antigenic exposure, IgM is the first antibody secreted by the adaptive immune system, and after 3-4 wk, IgG is produced. IgM can persist in the blood for up to 3 mo, followed by its decline. However, in PBC, the level of IgM-related AMAs does not decline over the course of the disease, which does not align with the bacterial nature of antigens triggering the production of AMAs. With continuous exposure to thymus-independent antigens and decreased immune tolerance to them, IgM synthesis can become stable[16]. However, there is low likelihood that bacterial antigen is constantly present in patients with PBC and triggers the production of AMAs[10]. It is more logical to assume that the antigen is from the patients’ own tissues, namely the epithelium of the biliary tract. The production of AMAs in patients with PBC is initiated once E2 PDC becomes an immunomodified antigen, leaves the mitochondria, exits the cholangiocyte, enters the blood, and meets immunocompetent T and B lymphocytes which recognize it as a foreign antigen. To date, the triggers and mechanisms that initiate these processes in cholangiocytes remain unknown.

In the last decade, scientific data have shown that the “protective umbrella” of bicarbonate (HCO3-) protects cholangiocytes from the toxic effects of bile acids. In PBC, the production of HCO3- decreases, which leads to increased bile acid intake into cholangiocytes (theory of defective “biliary HCO3- umbrella”). Based on these data, we hypothesize that the gradual accumulation of bile acids in BECs may serve as a trigger mechanism for AMAs formation, ductulopenia development, and one of the early clinical signs of PBC, namely weakness in the asymptomatic stage.

**AGGRESSIVE AND DEFENSE FACTORS OF CHOLANGIOCYTES**

Bile is an aggressive medium for cholangiocytes, which are epithelial cells lining the intrahepatic and extrahepatic bile ducts. The presence of bile acids in bile, which have potent detergent properties, can cause damage to the cell membranes of cholangiocytes. Hydrophobic bile acids are cytotoxic to many cell types[17]. However, BECs under physiological conditions are exposed to very high (millimolar) concentrations of hydrophobic bile acids without signs of cytotoxicity[18], indicating the presence of mechanisms protecting cholangiocytes from the toxic effects of bile acids.

The conjugation of bile acids and formation of mixed micelles with cholesterol and phospholipids are considered defense mechanisms at the levels of hepatocytes, bile capillaries, and Hering’s canals[18]. Defense factors that enter the bile during its passage through bile ducts include the production and secretion of mucin and HCO3-[19]. Under physiological conditions, the main function of cholangiocytes is biliary secretion of HCO3-[20]. HCO3- is produced by cholangiocytes lining the biliary tree. Mucin glycoprotein is produced by peribiliary glands (PBGs)[21], which are located in the wall of large intrahepatic and extrahepatic bile ducts and are directly connected with the bile duct lumen. Experimental evidence indicates that the glycocalyx, which covers the apical surface of large cholangiocyte membranes with glycosylated mucins and other glycan-containing membrane glycoproteins, stabilizes the biliary HCO3- umbrella, thereby helping to protect human large cholangiocytes from bile acid toxicity[22]. In addition, the mucin produced by PBGs protects the cholangiocytes of only large bile ducts[19]. Thus, the cholangiocytes of large intrahepatic and extrahepatic bile ducts have dual protection: The mucin produced by PBGs and HCO3-. Intralobular, interlobular, and septal bile ducts do not contain PBGs, which is accompanied by the absence of mucin in them[21]. As a result, only HCO3- serves as a factor of BEC defense at the levels of intralobular, interlobular, and septal ducts. Under physiological conditions, there is a balance between aggressive factors (bile acids) and defense factors (HCO3- and/or mucin secretion).

**CHOLANGIOCYTE DEFENSE MECHANISMS**

Cholangiocytes are polarized epithelial cells that line the intrahepatic and extrahepatic bile ducts and are responsible for regulating bile volume, modifying bile, and maintaining bile pH (alkalinity)[23,24]. They play an important role in modifying the composition of primary bile by secreting water, chloride (Cl-), and HCO3-[25], and by absorbing bile acid salts, amino acids, and glucose. Small and large cholangiocytes are distinguished depending on their size and location in small and large bile ducts[26]. They are differently involved in the processes of secretion and absorption[27]. The secretion of HCO3- with human bile accounts for 25%-40% of the total volume of secreted bile and maintains physiologic pH in the lumen of bile ducts[17,28,29].

In the process of bile formation, predominantly conjugated bile acids and a minimal amount of unconjugated bile acids enter the bile capillary. Under physiological conditions, both conjugated and unconjugated bile acids are secreted into bile by hepatocytes in anionic (deprotonated, ionized, negatively charged) form[30]. HCO3-, which is secreted by cholangiocytes into the lumen of the bile duct, creates a slightly alkaline pH of hepatic bile due to its buffering properties, keeping bile acids in a deprotonated state. The ionized form of bile acids are impermeable to BECs due to the presence of negatively charged HCO3- molecules on the apical surface of the cytoplasmic membrane of cholangiocytes[30]. Thus, the secretion of HCO3- ions protects cholangiocytes from uncontrolled transmembrane bile acid entrance and their cytotoxicity. This protective mechanism, which preserves cholangiocytes and normal bile flow along the biliary tree, is called the biliary HCO3- umbrella.

**MAIN REGULATORS OF HCO3- PRODUCTION AND SECRETION BY CHOLANGIOCYTES**

The pH fluctuation in bile ducts depends on the rate of HCO3- production by cholangiocytes. The signaling pathways regulating HCO3- secretion differ in large and small cholangiocytes[31]. In small cholangiocytes, activation of HCO3- secretion is due to biliary adenosine triphosphate (ATP) secreted from upstream hepatocytes of Hering’s canals (Figure 1). Cholangiocytes express apical membrane proteins of the purinergic receptor (P2YR) family, which are stimulated by ATP[32]. Luminal ATP binds to P2YR, stimulating intracellular calcium (Ca2+) release *via* inositol-1,4,5-trisphosphate receptor type 3 (InsP3R3)[33]. In cholangiocytes, InsP3R3 is the major receptor isoform localized in the apical region[31,34]; it is involved in InsP3R3-mediated cell signaling and Ca2+ secretion[35]. InsP3R3 is the only receptor that promotes the opening of intracellular Ca2+ channels and release of Ca2+ ions[34]. Ca2+ is one of the second messengers in cholangiocytes that modulates and regulates diverse cellular functions such as ion channel activation, secretion, cell proliferation, and apoptosis[34,36]. Ca2+ release from subapical stores in the endoplasmic reticulum triggers and locally activates transmembrane 16A Cl- channels (TMEM16A) on the apical membrane of cholangiocytes (Figure 1)[36-38]. The appearing Cl- concentration gradient on the apical membrane activates the Cl-/HCO3- anion exchanger 2 (AE2), also Slc4A2, which leads to the secretion of HCO3- into the lumen of the bile duct.

In large cholangiocytes, with the exception of the Ca2+-dependent pathway of HCO3- secretion, there is an additional mechanism involving the hormones secretin and somatostatin[39] (Figure 1). Secretin is produced by the S cells of the duodenal mucosa, and stimulates the production of HCO3- by the intestinal mucosa itself as well as by cholangiocytes and pancreatic ductular epithelial cells[39]. Secretin regulates the secretion of HCO3- and Cl- into bile by large cholangiocytes through interaction with secretin receptors (SRs) located on the basolateral membrane of BECs[39-42] (Figure 1).

As a result of this interaction, the formation of cyclic adenosine monophosphate (cAMP) is stimulated *via* G proteins. cAMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) through adenylate cyclase, resulting in the secretion of Cl- ions into the bile duct[28]. The appearing Cl- concentration gradient on the apical membrane of cholangiocytes activates AE2, which leads to the secretion of HCO3- into the bile duct lumen in exchange for the intracellular entry of Cl- ions into the cholangiocytes[20,24,26,43]. In parallel, ATP from cholangiocytes enters the bile duct lumen by exocytosis, which stimulates the secretion of HCO3- *via* a Ca2+-dependent mechanism[44]. SRs and CFTR are not found in small cholangiocytes; therefore, secretin is unable to stimulate the secretion and entry of HCO3- and Cl- into bile in small cholangiocytes[24]. However, a Ca2+-dependent mechanism of HCO3- secretion is present in both small and large cholangiocytes (Figure 1)[20,24]. Somatostatin, which binds to the somatostatin receptor, counteracts the stimulating effect of secretin, inhibits fluid secretion, and slows the production and entry of HCO3- from cholangiocytes into the lumen of the bile duct[45].

**MECHANISMS OF BILE ACID PROTONATION-DEPROTONATION AND THEIR ENTRY INTO CHOLANGIOCYTES**

Uncontrolled, carrier-independent, passive diffusion of unconjugated primary bile acids into BECs is determined by their polarity and degree of protonation[18,46,47]. Protonation of bile acids is an exponential function of pH. When the pH of hepatic bile acidifies, bile acids may undergo protonation. The degree of protonation of bile acids depends on both their dissociation constant (pKa) and the pH of the bile. The pKa values for unconjugated primary bile acids are 5-6[48-50]. Conjugation of primary bile acids with amino acids reduces pKa values to 4-5 for conjugates with glycine and to 1-2 for conjugates with taurine, which improves their solubility in water and reduces their lipopHilicity[48-50]. The low pKa values of the taurine conjugates of primary bile acids indicate that they are stronger acids than glycine conjugates. Therefore, taurine-conjugated bile acids are in a dissociated (deprotonated) form even at acidic bile pH values. Whereas glycine conjugates, with higher pKa values, are weak acids and will quickly change to a protonated state at the slightest acidification of bile[50].

Ionized (deprotonated, negatively charged) bile acids are unable to overcome the biliary HCO3- umbrella on the outer hemi leaflet of the apical cytoplasmic membrane of cholangiocytes[18,47]. Under normal physiological conditions, a small amount of unconjugated protonated primary bile acids is taken up by cholangiocytes. The neutral intracellular pH further promotes the transport of unconjugated protonated primary bile acids into the peribiliary vascular plexus with subsequent return to hepatocytes and re-release into biliary capillaries[51]. Such a biliary-hepatic shunt aims to prevent the accumulation of toxic bile acids with strong detergent properties in cholangiocytes[18,47].

Conjugated bile acids can be transported through the apical and basolateral membranes of cholangiocytes with the aid of specific transporters[26,52-56]. Conjugates of bile acids with glycine in human hepatic bile account for three-quarters of all conjugated bile acids and have a pKa close to 4[57]. At physiologic pH (approximately 7.4), glycine conjugates of primary bile acids, as relatively weak acids, are partially protonated (nonpolar), which promotes their absorption by cholangiocytes in micromolar amounts. Small shifts in local pH to an acidic region in biliary ducts lead to an increase in protonated glycine conjugates of primary bile acids. A significant increase in the ratio of protonated:deprotonated glycine-conjugated bile acids will lead to increased absorption by cholangiocytes.

Bile acid conjugates with taurine in hepatic bile account for one-quarter of all conjugated bile acids. They are stronger acids and have a pKa of 1-2[57,58]. Therefore, changes in biliary pH have little effect on their protonation. Most of the taurine conjugates of bile acids are in anionic form and thus are not able to enter cholangiocytes. Therefore, taurine conjugates of primary bile acids are less toxic to cholangiocytes.

Active functioning of bile acid transporters in the basolateral membrane of cholangiocytes, as a rule, leads to the rapid removal of hydrophobic bile acids from the intracellular space and their delivery back into hepatocytes[59]. Therefore, the accumulation of toxic bile acids with detergent properties in cholangiocytes does not occur under normal conditions.

**THEORY OF DEFECTIVE BILIARY HCO3- UMBRELLA IN PBC**

In PBC, there is a reduction in the protective role of HCO3- for cholangiocytes. The theory ofdefective “biliary HCO3-umbrella” has been extensively discussed[1,17,22]. This theory is based on a number of clinical and experimental works showing insufficient HCO3- supply to the bile ducts in PBC, which leads to a shift in the pH of intraductal (hepatic) bile to the slightly acidic region and an increase in pH in cholangiocytes to the slightly alkaline region. The reasons for the insufficient production of HCO3- by cholangiocytes are unknown. The involvement of InsP3R3 and AE2 in this process is discussed. The expression of InsP3R3 and AE2 genes is reduced in the liver biopsy specimens and blood mononuclear cells of patients with PBC, indicating their dysfunction and involvement in the pathogenesis of this disease[60,61]. The decreased expression and activity of InsP3R3 and AE2 is associated with increased microRNA 506 (miR-506) expression in cholangiocytes[62]. MiRNAs are small noncoding RNAs 22-23 nucleotides long that inhibit gene expression by full or partial pairing with initial sequences located in the 3’-untranslated region (3’-UTR) of mRNA[62].

The 3’-UTR region of the mRNA of InsP3R3[62] and the 3’-UTR region of the mRNA of AE2[63] contain binding sites for miR-506. MiR-506 binding to the 3’-UTR regions of the mRNA of InsP3R3 and AE2 prevents the translation of these proteins. In this way, miR-506 is a regulator of InsP3R3 and AE2 expression (Figure 2). The expression of miR-506 likely undergoes epigenetic regulation and can vary by individual as a result of polymorpHisms in nuclear factor kappa B[30].

An increase in the amount and activity of miR-506, and X-linked miRNA, has been reported in the cholangiocytes of patients with PBC[63], which leads to the decreased expression and activity of InsP3R3 and AE2, potentially explaining the prevalence of this disease in women[30] (Figure 2).

Decreased expression and activity of InsP3R3 in cholangiocytes in PBC[64] impairs intracellular Ca2+ secretion and its use as a messenger in signaling to the transmembrane Cl- channel TMEM16A[44]. Impaired Ca2+ signaling in cholangiocytes in PBC is evidenced by the absence of ATP stimulation of P2YRs on the apical membrane[36]. Decreased Ca2+-dependent activity of TMEM16A on the apical membrane of cholangiocytes leads to the decreased secretion of Cl- ions into the lumen of bile ducts, which is accompanied by decreased activity of the chlorine/HCO3- anion exchanger and impaired secretion of biliary HCO3-. In models of cholangiocytes expressing miR-506, InsP3R3-mediated reduction in intracellular Ca2+ release and decreased fluid and HCO3- secretion into bile ducts has been shown[36,44]. Binding of miR-506 to the 3’-UTR of AE2 mRNA also contributes to decreased Cl-/HCO3- anion exchanger activity and decreased HCO3- secretion by cholangiocytes (Figure 2). Human cholangiocytes isolated from biopsy specimens of patients with PBC show decreased AE2 activity[65]. Thus, the homeostasis of intracellular pH (pHi) in cholangiocytes and bile duct pH in patients with PBC may undergo changes[30]. Changes in intra- and extracellular pH in PBC associated with the loss of InsP3R3 and decreased activity of AE2 promote the protonation of bile acids, their entry into cholangiocytes, and the development of damage to the latter[44].

Destruction of biliary epithelium of small intrahepatic bile ducts during the early asymptomatic stage of PBC is most likely related to the imbalance between the aggressive factors (bile acids) and defense factors (biliary HCO3- umbrella) of cholangiocytes. Because intralobular, interlobular, and septal bile ducts, which are damaged in PBC, do not contain PBGs producing mucin glycoproteins (mucin supraepithelial layer)[21], this defense mechanism for small cholangiocytes most likely does not play a pathogenetic role in the development of PBС.

**MECHANISM OF CHOLANGIOCYTE DAMAGE AND DESTABILIZATION OF BILIARY HCO3- UMBRELLA**

Decrease of HCO3- supply to bile ducts, due to a decrease in InsP3R3 and AE2 activity, will shift pH in the bile duct lumen to an acidic region[66]. Simultaneously, due to the retention and accumulation of HCO3- in the cytosol of cholangiocytes, there is gradual alkalinization of intracellular pHi in patients with PBC[30,65,67]. Complete AE2 deficiency will lead to intracellular alkalosis of cholangiocytes[61]. However, the reduced (rather than absent) expression of InsP3R3 and AE2 genes has been observed in patients with PBC[61].

A shift of pH to a slightly acidic region in the lumen of bile ducts will increase the amount of protonated unconjugated and glycine-conjugated primary bile acids. This will lead to their increased entry into the small cholangiocytes (intralobular, interlobular, septal) of the bile ducts. Once in the slightly alkaline pHi within the cholangiocytes, the protonated bile acids will undergo deprotonation. Alkalinization of pHi and ionization of glycine-conjugated and unconjugated primary bile acids within cholangiocytes reduces the process of their difundation from intracellular to peribiliary space. As a result, there is a delayed and gradual accumulation of glycine-conjugated and unconjugated primary bile acids in small cholangiocytes. The theory of defective biliary HCO3- umbrella helps to explain the intracellular uncontrolled increased entry and accumulation of bile acids in small BECs.

The presence of the mucin-containing glycocalyx layer on the apical surface of large cholangiocytes protects them from penetration and the damaging effect of protonated conjugated and unconjugated bile acids. Intracellular accumulation of hydrophobic bile acids is a prerequisite for their cytotoxic effects[68]. As strong detergents, they are able to solubilize phospholipids and cholesterol from membrane structures of cholangiocytes, which leads to damage and destruction of cytoplasmic membrane and membranes of cell organelles (Figure 3). Thus, the entry and accumulation of unconjugated bile acids with stronger detergent properties in small cholangiocytes is more toxic for the cell than the accumulation of conjugated bile acids.

The chronic damaging effect of bile acids on membrane structures triggers accelerated senescence, necrosis, and/or apoptosis of BECs[69]. Bile acids destroy the membranes of cell organelles and nuclear membrane of cholangiocytes with the release of apoptogenic factors. The barrier function of the biliary epithelium is impaired, resulting in concomitant damage, inflammation, and oxidative stress. Cytokines, chemokines, and pro-inflammatory mediators released by cholangiocytes probably stimulate apoptotic and proliferative responses as well as activate fibrogenesis[70]. Bile acids also mediate their toxic, apoptotic effects through specific signaling pathways at the intracellular level. The intrinsic apoptotic pathway is activated, including mitochondrial translocation of B-cell lymphoma 2-associated X protein, release of cytochrome C from mitochondria, activation of caspase 3, cleavage of poly (ADP-ribose) polymerase, and DNA fragmentation[71]. There is evidence that miR-506 activates the apoptosis pathway upon stimulation with toxic bile acids[66].

Proinflammatory cytokines additionally increase miR-506 expression[30]. A vicious circle develops that supports senescence, apoptosis, and proliferation of cholangiocytes. Ultimately, ductulopenia develops[30]. Together, this reflects the direct effects of bile acids on cholangiocytes rather than the nonspecific effects resulting from periportal inflammation[31].

From a pathophysiologic point of view, common to all cholangiopathies is the coexistence of cholangiocyte death and proliferation, as well as various degrees of portal inflammation and fibrosis[70]. Cell death induces the activation of inflammatory and profibrogenic pathways that trigger the development and progression of fibrosis, which gradually leads to small bile duct ductulopenia[72]. The conceptual mechanisms of these processes have been described in reviews[69,72].

Disruption of apoptosis is considered a trigger of PBC and already in the asymptomatic stage leads to the development of small bile duct ductulopenia, one of the early morphologic signs of the disease[73]. Apoptosis depends on mitochondrial permeabilization associated with excessive intracellular accumulation of bile acids[74-76]. In addition, bile acids and incomplete apoptosis of BECs diverted to necrosis can lead to pathogenic effects on intracellular components with subsequent generation of AMAs[77].

**MECHANISM OF MITOCHONDRIAL PERMEABILIZATION AND AMAs FORMATION**

Solubilization of phospholipids and cholesterol from the outer membrane of mitochondria by bile acids leads to their permeabilization[78]. There is an increase in the permeability of the mitochondrial outer membrane to ions and solutes[71,78]. There is leakage of the contents of the intermembrane space into the cytosol and loss of membrane potential. Mitochondria swell, their outer membrane swells, and the release of apoptogenic factors occurs[78]. The inner mitochondrial membrane, the main target for AMA formation, is opened. Further solubilization by bile acids of phospholipids and cholesterol from the inner membrane and destruction of mitochondria can lead to the release and degradation of PDC. The latter includes three enzymes: E1 PDC, E2 PDC, and dihydrolipoyl dehydrogenase (E3 PDC)[73]. Each of these enzymes, in addition to the protein part, has cofactors: E1 PDC contains thiamine pyrophosphate as a cofactor; E2 PDC contains lipoic acid and coenzyme A; and E3 PDC contains flavin adenine dinucleotide and nicotinamide adenine dinucleotide. E1 and E3 PDC are protein complexes that do not contain lipid components. Therefore, they are unlikely to be affected by bile acids accumulated in cholangiocytes, since they have an effect on lipid components. Sera from PBC patients do not show serologically detectable reactivity against the E1 and E3 components of PDC[79].

E2 PDC is a lipoprotein with two lipoic acid binding sites[8]. E2 PDCs contain an essential lysine residue in the lipoyl domain to which lipoic acid is covalently attached[8]. The lipoic-lysine bond at position 173 is highly conserved across species and is essential for antigen recognition[80]. AMAs target immunodominant epitopes containing lipoic acid.

The importance of chemical xenobiotics capable of modifying lipoic acid in E2 PDC has been previously shown for the appearance of serologic reactivity of this complex[81,82]. Alteration of the conformational structure of the lipoyl domain of E2 PDC, due to chemical modification of lipoic acid may contribute to the loss of immune tolerance[83,84]. Most likely, such chemical modifiers in PBC are bile acids accumulating in cholangiocytes upon loss of the protective properties of the biliary HCO3- umbrella. Bile acids can interact with the lipoic acid of the antigen-recognized E2 PDC. The result of such an interaction may be immunomodification of the E2 PDC complex with acquisition of autoantigenic properties and loss of immune tolerance[66]. This assumption is supported by a number of studies performed at the end of the last century. In these works, it was shown that the main immunogenic region on E2 PDC recognized by sera from patients with PBC is localized in the lipoyl-containing domain[85-87]. The lipoic acid content of E2 PDC is thought to play a role as a potent adjuvant[88]. The presentation of immunomodified E2 PDC complex to lymphocytes can lead to stimulation of the T-cell subpopulation and specific production of AMAs[66,88,89].

A defective biliary HCO3- umbrella triggers a continuous and endless process of accumulation and detergent action of bile acids on small cholangiocytes with the formation of AMAs. Since the disruption of HCO3- entry into the lumen of the bile duct is constant, the production of AMAs will be continuous. As a result, an elevated level of IgM (M2) will be constantly maintained in the plasma of PBC patients. The appearance of AMAs in serum is another early immunologic pathognomonic sign of PBC, which occurs in the asymptomatic stage of the disease.

**DYSFUNCTION OF THE PDC COMPLEX AND THE FIRST CLINICAL SIGNS OF THE ASYMPTOMATIC STAGE OF PBC**

AMAs detection in the asymptomatic stage of the disease is accompanied by the appearance of the first subjective clinical signs, namely weakness, malaise, fatigue, and decreased performance[90]. Fatigue is the most common symptom of PBC in the asymptomatic and early stage of the disease[91-93], occurring in about 40%-80% of patients[94,95]. However, there is no correlation between fatigue and the severity or duration of the disease[95-98].

The mechanism underlying fatigue development is closely related to gradually progressive energy deficiency[99]. The latter is most likely related to the involvement of the PDC in the pathologic process of PBC development. The PDC is a very important metabolic enzyme. PDC functions in every cell and is required for the conversion of pyruvate to acetyl-CoA, which is incorporated into the Krebs cycle and is essential for the body to obtain energy in the form of ATP[73]. As mitochondria in cholangiocytes permeabilize and PDC becomes involved in AMAs production, there is a gradual decrease in ATP synthesis. This leads to the development of local energy deficiency, which in turn, enhances the senescence and apoptosis processes of small BECs initiated by bile acids. A vicious cycle occurs, contributing to the progression of ductulopenia and AMAs formation. In this case, AMAs are able to react with polypeptides including E2 PDC in the mitochondria of almost any cell. It has been shown that antibodies to PBC cross-react with polypeptides in the mitochondria of beef heart, presumably related to E2 PDC[100]. ATP production decreases and energy deficiency develops throughout the organism.

The development of energy deficiency is accompanied by an increase in glycogenolysis and a decrease in glycogenogenesis. The study by Green *et* *al*[101] showed that in the initial stages of PBC, there was a gradual decrease in glycogen stores in the liver associated with increased glycogenolysis and decreased glycogenogenesis. The authors also demonstrated that glucokinase activity significantly dropped (down to zero) in patients with PBC, indicating a decrease in glycogen formation in the liver[101]. At the same time, hexokinase (phosphorylates hexoses), which is responsible for glycogen synthesis mainly in muscles, was significantly increased in patients with PBC during this period compared to healthy individuals[101]. As a result of the developing energy deficiency in the asymptomatic stage of the disease, the first clinical signs of expressed weakness, rapid fatigue, decreased performance, functional status, and quality of life appear in patients with PBC[90,102-104].

**CONCLUSION**

Based on the growing body of knowledge on the molecular mechanisms underlying the development of cholangiocyte damage in patients with PBC, we proposed a hypothesis to explain the pathogenesis of the initial morphologic (ductulopenia), immunologic (AMAs) and clinical (weakness, malaise, rapid fatigue) signs of the disease in the asymptomatic stage (Figure 4).

Evidence suggests that in susceptible individuals, an unknown initial trigger causes an X-linked epigenetic change that leads to gene reactivation and increased expression of miR-506[30]. The increased synthesis and activation of miR-506 leads to inhibition of InsP3R3 and AE2 translation[105]. As a result, HCO3- entry into the bile duct lumen is reduced and HCO3- accumulation in the cytosol of cholangiocytes occurs[30]. Changes in extra- and intracellular pH alter the protonation (in the lumen of the bile duct) and deprotonation (intracholangiocyte) of bile acids, leading to an increase in the uncontrolled entry and accumulation of unconjugated and glycine-conjugated bile acids into the BECs.

The detergent properties of bile acids trigger cell membrane disruption, senescence and apoptosis of cholangiocytes, mitochondrial permeabilization, destruction and immunomodification of E2 PDC, followed by AMAs formation. Senescence, apoptosis, and proliferation of cholangiocytes lead to the gradual development of ductulopenia. The involvement of PDC in the pathological process contributes to insufficient ATP synthesis, development of energy deficiency, and occurrence of the nonspecific clinical sign of fatigue. The development of ductulopenia is accompanied by the development of intrahepatic cholestasis. Cholangiocytes are the main target in the initial stage of PBC. However, as soon as cholestasis develops, hepatocytes are also involved in the pathological process, which leads to their damage[30].

**REFERENCES**

1 **Prieto J**, Banales JM, Medina JF. Primary biliary cholangitis: pathogenic mechanisms. *Curr Opin Gastroenterol* 2021; **37**: 91-98 [PMID: 33332913 DOI: 10.1097/MOG.0000000000000703]

2 **Reshetnyak VI**. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. *World J Gastroenterol* 2015; **21**: 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683]

3 **de Veer RC**, van Hooff MC, da Silva G, Harms MH, Metselaar HJ, Willemse J, Utomo E, van der Meer AJ. Quality of life in Dutch patients with primary biliary cholangitis: Discrepancies between patients' perspectives and objective disease parameters. *Hepatol Res* 2023; **53**: 401-408 [PMID: 36635224 DOI: 10.1111/hepr.13880]

4 **Neuberger J**, Thomson R. PBC and AMA--what is the connection? *Hepatology* 1999; **29**: 271-276 [PMID: 9862877 DOI: 10.1002/hep.510290126]

5 **Chen R**, Tang R, Ma X, Gershwin ME. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis. *Clin Liver Dis* 2022; **26**: 583-611 [PMID: 36270718 DOI: 10.1016/j.cld.2022.06.003]

6 **Mutimer DJ**, Fussey SP, Yeaman SJ, Kelly PJ, James OF, Bassendine MF. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. *Hepatology* 1989; **10**: 403-407 [PMID: 2673968 DOI: 10.1002/hep.1840100402]

7 **Van Norstrand MD**, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, Dickson ER, Homburger HA. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. *Hepatology* 1997; **25**: 6-11 [PMID: 8985257 DOI: 10.1002/hep.510250103]

8 **Coppel RL**, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, Whittingham S, Gershwin ME. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. *Proc Natl Acad Sci U S A* 1988; **85**: 7317-7321 [PMID: 3174635 DOI: 10.1073/pnas.85.19.7317]

9 **Krams SM**, Surh CD, Coppel RL, Ansari A, Ruebner B, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. *Hepatology* 1989; **9**: 411-416 [PMID: 2920998 DOI: 10.1002/hep.1840090311]

10 **Fussey SP**, Lindsay JG, Fuller C, Perham RN, Dale S, James OF, Bassendine MF, Yeaman SJ. Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. *Hepatology* 1991; **13**: 467-474 [PMID: 1999318 DOI: 10.1002/hep.1840130314]

11 **Lindenborn-Fotinos J**, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. *Hepatology* 1985; **5**: 763-769 [PMID: 2411647 DOI: 10.1002/hep.1840050510]

12 **Frazer IH**, Mackay IR, Jordan TW, Whittingham S, Marzuki S. Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. *J Immunol* 1985; **135**: 1739-1745 [PMID: 2410503]

13 **Stemerowicz R**, Hopf U, Möller B, Wittenbrink C, Rodloff A, Reinhardt R, Freudenberg M, Galanos C. Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of enterobacteriaceae? *Lancet* 1988; **2**: 1166-1170 [PMID: 2903378 DOI: 10.1016/s0140-6736(88)90235-8]

14 **Khor SS**, Ueno K, Nishida N, Kawashima M, Kawai Y, Aiba Y, Hitomi Y, Nagasaki M, Nakamura M, Tokunaga K. Novel HLA allele associations with susceptibility, staging, symptomatic state, autoimmune hepatitis and hepatocellular carcinoma events for primary biliary cholangitis in the Japanese population. *Front Immunol* 2023; **14**: 1151502 [PMID: 37325616 DOI: 10.3389/fimmu.2023.1151502]

15 **Burroughs AK**, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. *Gut* 1984; **25**: 133-137 [PMID: 6363217 DOI: 10.1136/gut.25.2.133]

16 **Loginov AS,** Tsaregorodtseva TM, Zotina MM. The immune system and digestive diseases. Moscow: Meditsina Publishers, 1986: 42-65 Available from: https://search.rsl.ru/ru/record/01008480564?ysclid=llov5y33xp23524599

17 **Hohenester S**, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. *Hepatology* 2012; **55**: 173-183 [PMID: 21932391 DOI: 10.1002/hep.24691]

18 **Hofmann AF**. The enterohepatic circulation of bile acids in mammals: form and functions. *Front Biosci (Landmark Ed)* 2009; **14**: 2584-2598 [PMID: 19273221 DOI: 10.2741/3399]

19 **Matsubara T**, Kozaka K, Matsui O, Nakanuma Y, Uesaka K, Inoue D, Yoneda N, Yoshida K, Kitao A, Yokka A, Koda W, Gabata T, Kobayashi S. Peribiliary glands: development, dysfunction, related conditions and imaging findings. *Abdom Radiol (NY)* 2020; **45**: 416-436 [PMID: 31707436 DOI: 10.1007/s00261-019-02298-4]

20 **Banales JM**, Prieto J, Medina JF. Cholangiocyte anion exchange and biliary bicarbonate excretion. *World J Gastroenterol* 2006; **12**: 3496-3511 [PMID: 16773707 DOI: 10.3748/wjg.v12.i22.3496]

21 **Carpino G**, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, Wang Y, Semeraro R, Anceschi M, Brunelli R, Alvaro D, Reid LM, Gaudio E. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. *J Anat* 2012; **220**: 186-199 [PMID: 22136171 DOI: 10.1111/j.1469-7580.2011.01462.x]

22 **Maillette de Buy Wenniger LJ**, Hohenester S, Maroni L, van Vliet SJ, Oude Elferink RP, Beuers U. The Cholangiocyte Glycocalyx Stabilizes the 'Biliary HCO3 Umbrella': An Integrated Line of Defense against Toxic Bile Acids. *Dig Dis* 2015; **33**: 397-407 [PMID: 26045275 DOI: 10.1159/000371864]

23 **Esteller A**. Physiology of bile secretion. *World J Gastroenterol* 2008; **14**: 5641-5649 [PMID: 18837079 DOI: 10.3748/wjg.14.5641]

24 **Hrncir HR**, Gracz AD. Cellular and transcriptional heterogeneity in the intrahepatic biliary epithelium. *Gastro Hep Adv* 2023; **2**: 108-120 [PMID: 36593993 DOI: 10.1016/j.gastha.2022.07.015]

25 **Hirata K**, Nathanson MH. Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver. *Gastroenterology* 2001; **121**: 396-406 [PMID: 11487549 DOI: 10.1053/gast.2001.26280]

26 **Tabibian JH**, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Physiology of cholangiocytes. *Compr Physiol* 2013; **3**: 541-565 [PMID: 23720296 DOI: 10.1002/cphy.c120019]

27 **Marzioni M**, Glaser SS, Francis H, PHinizy JL, LeSage G, Alpini G. Functional heterogeneity of cholangiocytes. *Semin Liver Dis* 2002; **22**: 227-240 [PMID: 12360417 DOI: 10.1055/s-2002-34501]

28 **Kanno N**, LeSage G, Glaser S, Alpini G. Regulation of cholangiocyte bicarbonate secretion. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G612-G625 [PMID: 11518673 DOI: 10.1152/ajpgi.2001.281.3.G612]

29 **Masyuk AI**, Masyuk TV, Tietz PS, Splinter PL, LaRusso NF. Intrahepatic bile ducts transport water in response to absorbed glucose. *Am J Physiol Cell Physiol* 2002; **283**: C785-C791 [PMID: 12176735 DOI: 10.1152/ajpcell.00118.2002]

30 **Chang JC**, Go S, Verhoeven AJ, Beuers U, Oude Elferink RPJ. Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis; a new hypothesis. *Biochim Biophys Acta Mol Basis Dis* 2018; **1864**: 1232-1239 [PMID: 28962898 DOI: 10.1016/j.bbadis.2017.09.022]

31 **Rodrigues MA**, Gomes DA, Nathanson MH. Calcium Signaling in Cholangiocytes: Methods, Mechanisms, and Effects. *Int J Mol Sci* 2018; **19** [PMID: 30563259 DOI: 10.3390/ijms19123913]

32 **Dranoff JA**, Masyuk AI, Kruglov EA, LaRusso NF, Nathanson MH. Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G1059-G1067 [PMID: 11557527 DOI: 10.1152/ajpgi.2001.281.4.G1059]

33 **Nathanson MH**, Burgstahler AD, Mennone A, Boyer JL. Characterization of cytosolic Ca2+ signaling in rat bile duct epithelia. *Am J Physiol* 1996; **271**: G86-G96 [PMID: 8760111 DOI: 10.1152/ajpgi.1996.271.1.G86]

34 **Lemos FO**, Florentino RM, Lima Filho ACM, Dos Santos ML, Leite MF. Inositol 1,4,5-trisphosphate receptor in the liver: Expression and function. *World J Gastroenterol* 2019; **25**: 6483-6494 [PMID: 31802829 DOI: 10.3748/wjg.v25.i44.6483]

35 **Berridge MJ**, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* 2003; **4**: 517-529 [PMID: 12838335 DOI: 10.1038/nrm1155]

36 **Trampert DC**, Nathanson MH. Regulation of bile secretion by calcium signaling in health and disease. *Biochim Biophys Acta Mol Cell Res* 2018; **1865**: 1761-1770 [PMID: 29787781 DOI: 10.1016/j.bbamcr.2018.05.010]

37 **Li Q**, Dutta A, Kresge C, Bugde A, Feranchak AP. Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(-) channels. *Hepatology* 2018; **68**: 187-199 [PMID: 29360145 DOI: 10.1002/hep.29804]

38 **Dutta AK**, Khimji AK, Kresge C, Bugde A, Dougherty M, Esser V, Ueno Y, Glaser SS, Alpini G, Rockey DC, Feranchak AP. Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. *J Biol Chem* 2011; **286**: 766-776 [PMID: 21041307 DOI: 10.1074/jbc.M110.164970]

39 **Afroze S**, Meng F, Jensen K, McDaniel K, Rahal K, Onori P, Gaudio E, Alpini G, Glaser SS. The physiological roles of secretin and its receptor. *Ann Transl Med* 2013; **1**: 29 [PMID: 25332973 DOI: 10.3978/j.issn.2305-5839.2012.12.01]

40 **Boyer JL**. Bile duct epithelium: frontiers in transport physiology. *Am J Physiol* 1996; **270**: G1-G5 [PMID: 8772494 DOI: 10.1152/ajpgi.1996.270.1.G1]

41 **Alpini G**, PHinizy JL, Glaser S, Francis H, Benedetti A, Marucci L, LeSage G. Development and characterization of secretin-stimulated secretion of cultured rat cholangiocytes. *Am J Physiol Gastrointest Liver Physiol* 2003; **284**: G1066-G1073 [PMID: 12540366 DOI: 10.1152/ajpgi.00260.2002]

42 **Banales JM**, Arenas F, Rodríguez-Ortigosa CM, Sáez E, Uriarte I, Doctor RB, Prieto J, Medina JF. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. *Hepatology* 2006; **43**: 266-275 [PMID: 16440368 DOI: 10.1002/hep.21042]

43 **Alvaro D**, Cho WK, Mennone A, Boyer JL. Effect of secretion on intracellular pH regulation in isolated rat bile duct epithelial cells. *J Clin Invest* 1993; **92**: 1314-1325 [PMID: 8397224 DOI: 10.1172/JCI116705]

44 **Minagawa N**, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues MA, Lesage G, Akiba Y, Kaunitz JD, Ehrlich BE, Larusso NF, Nathanson MH. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. *Gastroenterology* 2007; **133**: 1592-1602 [PMID: 17916355 DOI: 10.1053/j.gastro.2007.08.020]

45 **Tietz PS**, Alpini G, Pham LD, Larusso NF. Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. *Am J Physiol* 1995; **269**: G110-G118 [PMID: 7631787 DOI: 10.1152/ajpgi.1995.269.1.G110]

46 **Amelsberg A**, Schteingart CD, Ton-Nu HT, Hofmann AF. Carrier-mediated jejunal absorption of conjugated bile acids in the guinea pig. *Gastroenterology* 1996; **110**: 1098-1106 [PMID: 8612999 DOI: 10.1053/gast.1996.v110.pm8612999]

47 **Masyuk AI,** Masyuk TV, Larusso NF. Physiology of Cholangiocytes. *Physiology of the Gastrointestinal Tract (Fourth Edition)* 2006; **2**: 1505-1533 [DOI: 10.1016/B978-012088394-3/50022-2]

48 **Fini A,** Ferocia G, Roda A. Acidity in bile acid systems. *Polyhedron* 2002; **21**:1421-1427 [DOI: 10.1016/s0277-5387(02)00968-3]

49 **Bortolini O**, Bernardi T, Fantin G, Ferretti V, Fogagnolo M. Relative acidity scale of glycine- and taurine-conjugated bile acids through ESI-MS measurements. *Steroids* 2011; **76**: 596-602 [PMID: 21371488 DOI: 10.1016/j.steroids.2011.02.028]

50 **Pavlović N**, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, Mikov M. Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. *Front Pharmacol* 2018; **9**: 1283 [PMID: 30467479 DOI: 10.3389/fphar.2018.01283]

51 **Dawson PA,** Shneider BL, Hofmann AF. CHAPTER 56 - Bile Formation and the Enterohepatic Circulation. *Physiology of the Gastrointestinal Tract (Fourth Edition)* **2006**:1437-1462 [DOI: 10.1016/B978-012088394-3/50059-33]

52 **Alpini G**, Glaser SS, Rodgers R, PHinizy JL, Robertson WE, Lasater J, Caligiuri A, Tretjak Z, LeSage GD. Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes. *Gastroenterology* 1997; **113**: 1734-1740 [PMID: 9352879 DOI: 10.1053/gast.1997.v113.pm9352879]

53 **Benedetti A**, Di Sario A, Marucci L, Svegliati-Baroni G, Schteingart CD, Ton-Nu HT, Hofmann AF. Carrier-mediated transport of conjugated bile acids across the basolateral membrane of biliary epithelial cells. *Am J Physiol* 1997; **272**: G1416-G1424 [PMID: 9227477 DOI: 10.1152/ajpgi.1997.272.6.G1416]

54 **Hirohashi T**, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). *J Biol Chem* 2000; **275**: 2905-2910 [PMID: 10644759 DOI: 10.1074/jbc.275.4.2905]

55 **Lazaridis KN**, Pham L, Tietz P, Marinelli RA, deGroen PC, Levine S, Dawson PA, LaRusso NF. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. *J Clin Invest* 1997; **100**: 2714-2721 [PMID: 9389734 DOI: 10.1172/JCI119816]

56 **Lazaridis KN**, Tietz P, Wu T, Kip S, Dawson PA, LaRusso NF. Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. *Proc Natl Acad Sci U S A* 2000; **97**: 11092-11097 [PMID: 10984521 DOI: 10.1073/pnas.200325297]

57 **Carey MC.** Physical-chemical properties of bile acids and their salts. *New Comprehensive Biochemistry* 1985; **12**: 345-403 [DOI: 10.1016/S0167-7306(08)60689-4]

58 **Hofmann AF**. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. *Hepatology* 2009; **49**: 1403-1418 [PMID: 19296471 DOI: 10.1002/hep.22789]

59 **Luo ZL**, Cheng L, Wang T, Tang LJ, Tian FZ, Xiang K, Cui L. Bile Acid Transporters Are Expressed and Heterogeneously Distributed in Rat Bile Ducts. *Gut Liver* 2019; **13**: 569-575 [PMID: 30919600 DOI: 10.5009/gnl18265]

60 **Prieto J**, Qian C, García N, Díez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. *Gastroenterology* 1993; **105**: 572-578 [PMID: 8335211 DOI: 10.1016/0016-5085(93)90735-u]

61 **Medina JF**, Martínez-Ansó, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. *Hepatology* 1997; **25**: 12-17 [PMID: 8985258 DOI: 10.1002/hep.510250104]

62 **Ananthanarayanan M**, Banales JM, Guerra MT, Spirli C, Munoz-Garrido P, Mitchell-Richards K, Tafur D, Saez E, Nathanson MH. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. *J Biol Chem* 2015; **290**: 184-196 [PMID: 25378392 DOI: 10.1074/jbc.M114.587030]

63 **Banales JM**, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, Tietz Bogert PS, Bujanda L, Prieto J, Medina JF, LaRusso NF. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. *Hepatology* 2012; **56**: 687-697 [PMID: 22383162 DOI: 10.1002/hep.25691]

64 **Shibao K**, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. *Gastroenterology* 2003; **125**: 1175-1187 [PMID: 14517800 DOI: 10.1016/s0016-5085(03)01201-0]

65 **Melero S**, Spirlì C, Zsembery A, Medina JF, Joplin RE, Duner E, Zuin M, Neuberger JM, Prieto J, Strazzabosco M. Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. *Hepatology* 2002; **35**: 1513-1521 [PMID: 12029638 DOI: 10.1053/jhep.2002.33634]

66 **Erice O**, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, Santos-Laso A, Arbelaiz A, Jimenez-Agüero R, Fernandez-Irigoyen J, Santamaria E, Torrano V, Carracedo A, Ananthanarayanan M, Marzioni M, Prieto J, Beuers U, Oude Elferink RP, LaRusso NF, Bujanda L, Marin JJG, Banales JM. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. *Hepatology* 2018; **67**: 1420-1440 [PMID: 28922472 DOI: 10.1002/hep.29533]

67 **Concepcion AR**, Lopez M, Ardura-Fabregat A, Medina JF. Role of AE2 for pHi regulation in biliary epithelial cells. *Front Physiol* 2013; **4**: 413 [PMID: 24478713 DOI: 10.3389/fphys.2013.00413]

68 **Komichi D**, Tazuma S, Nishioka T, Hyogo H, Une M, Chayama K. Unique inhibition of bile salt-induced apoptosis by lecithins and cytoprotective bile salts in immortalized mouse cholangiocytes. *Dig Dis Sci* 2003; **48**: 2315-2322 [PMID: 14714619 DOI: 10.1023/b:ddas.0000007869.67105.27]

69 **Borkham-Kamphorst E**, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. *Cytokine Growth Factor Rev* 2016; **28**: 53-61 [PMID: 26547628 DOI: 10.1016/j.cytogfr.2015.10.002]

70 **Strazzabosco M**. Transport systems in cholangiocytes: their role in bile formation and cholestasis. *Yale J Biol Med* 1997; **70**: 427-434 [PMID: 9626763]

71 **Chang JC**, Go S, de Waart DR, Munoz-Garrido P, Beuers U, Paulusma CC, Oude Elferink R. Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes. *Hepatology* 2016; **64**: 522-534 [PMID: 26991014 DOI: 10.1002/hep.28550]

72 **Trautwein C**, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. *J Hepatol* 2015; **62**: S15-S24 [PMID: 25920084 DOI: 10.1016/j.jhep.2015.02.039]

73 **Saipiyeva D,** Askarov M, Tuganbekov T, Rustemova K, Grigorevsky V, Dossatayeva G, Tostanovskaya N. Antimitochondrial and antinuclear antibodies in primary biliary cholangitis. *Journal of Clinical Medicine of Kazakhstan* 2019; **2**: 16-23 [DOI: 10.23950/1812-2892-JCMK-00681]

74 **Szalai G**, Krishnamurthy R, Hajnóczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. *EMBO J* 1999; **18**: 6349-6361 [PMID: 10562547 DOI: 10.1093/emboj/18.22.6349]

75 **Csordás G**, Thomas AP, Hajnóczky G. Quasi-synaptic calcium signal transmission between endoplasmic reticulum and mitochondria. *EMBO J* 1999; **18**: 96-108 [PMID: 9878054 DOI: 10.1093/emboj/18.1.96]

76 **Ichas F**, Jouaville LS, Mazat JP. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. *Cell* 1997; **89**: 1145-1153 [PMID: 9215636 DOI: 10.1016/s0092-8674(00)80301-3]

77 **Berg CP**, Stein GM, Keppeler H, Gregor M, Wesselborg S, Lauber K. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. *Apoptosis* 2008; **13**: 63-75 [PMID: 18060504 DOI: 10.1007/s10495-007-0157-6]

78 **Halestrap AP**, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. *J Mol Cell Cardiol* 2015; **78**: 129-141 [PMID: 25179911 DOI: 10.1016/j.yjmcc.2014.08.018]

79 **Surh CD**, Roche TE, Danner DJ, Ansari A, Coppel RL, Prindiville T, Dickson ER, Gershwin ME. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. *Hepatology* 1989; **10**: 127-133 [PMID: 2473022 DOI: 10.1002/hep.1840100202]

80 **Gulamhusein AF**, Hirschfield GM. Pathophysiology of primary biliary cholangitis. *Best Pract Res Clin Gastroenterol* 2018; **34-35**: 17-25 [PMID: 30343706 DOI: 10.1016/j.bpg.2018.05.012]

81 **Ge S**, Xu Q, Li H, Shao T, Zhong F, Leung PSC, Shuai Z. Differential immune response to xenobiotic-modified self-molecule in simple and connective tissue disease-associated primary biliary cholangitis. *Liver Int* 2022; **42**: 2204-2215 [PMID: 35791754 DOI: 10.1111/liv.15360]

82 **Rieger R**, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. *J Autoimmun* 2007; **28**: 76-84 [PMID: 17360156 DOI: 10.1016/j.jaut.2007.02.003]

83 **Wang J**, Budamagunta MS, Voss JC, Kurth MJ, Lam KS, Lu L, Kenny TP, Bowlus C, Kikuchi K, Coppel RL, Ansari AA, Gershwin ME, Leung PS. Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. *J Immunol* 2013; **191**: 2126-2133 [PMID: 23894195 DOI: 10.4049/jimmunol.1301092]

84 **Naiyanetr P**, Butler JD, Meng L, Pfeiff J, Kenny TP, Guggenheim KG, Reiger R, Lam K, Kurth MJ, Ansari AA, Coppel RL, López-Hoyos M, Gershwin ME, Leung PS. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. *J Autoimmun* 2011; **37**: 209-216 [PMID: 21763105 DOI: 10.1016/j.jaut.2011.06.001]

85 **Rahmatullah M**, Gopalakrishnan S, Andrews PC, Chang CL, Radke GA, Roche TE. Subunit associations in the mammalian pyruvate dehydrogenase complex. Structure and role of protein X and the pyruvate dehydrogenase component binding domain of the dihydrolipoyl transacetylase component. *J Biol Chem* 1989; **264**: 2221-2227 [PMID: 2914903]

86 **Fussey SP**, Bassendine MF, James OF, Yeaman SJ. Characterisation of the reactivity of autoantibodies in primary biliary cirrhosis. *FEBS Lett* 1989; **246**: 49-53 [PMID: 2468528 DOI: 10.1016/0014-5793(89)80251-0]

87 **Surh CD**, Coppel R, Gershwin ME. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. *J Immunol* 1990; **144**: 3367-3374 [PMID: 1691756]

88 **Ohmori Hnt**, Yamauchi T, Yamamoto I. Augmentation of the antibody response by lipoic acid in mice. I. Analysis of the mode of action in an in vitro cultures system. *Jpn J Pharmacol* 1986; **42**: 135-140 [PMID: 2948041 DOI: 10.1254/jjp.42.135]

89 **Colapietro F**, Lleo A, Generali E. Antimitochondrial Antibodies: from Bench to Bedside. *Clin Rev Allergy Immunol* 2022; **63**: 166-177 [PMID: 34586589 DOI: 10.1007/s12016-021-08904-y]

90 **Sogolow ED**, Lasker JN, Short LM. Fatigue as a major predictor of quality of life in women with autoimmune liver disease: the case of primary biliary cirrhosis. *Womens Health Issues* 2008; **18**: 336-342 [PMID: 18420421 DOI: 10.1016/j.whi.2007.12.005]

91 **Kremer AE**, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, Steinberg A, McWherter CA, Choi YJ. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. *Liver Int* 2022; **42**: 112-123 [PMID: 34403559 DOI: 10.1111/liv.15039]

92 **Shamshtein D,** Liwinski T. Pathogenesis and management of fatigue in primary biliary cholangitis. *Fatigue: Biomedicine, Health & Behavior* 2022; **10**: 1-25 [DOI: 10.1080/21641846.2022.2034473]

93 **Abbas G**, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 313-319 [PMID: 20458334 DOI: 10.1038/nrgastro.2010.62]

94 **Witt-Sullivan H**, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, Pappas SC, Rankin J, Wanless IR. The demography of primary biliary cirrhosis in Ontario, Canada. *Hepatology* 1990; **12**: 98-105 [PMID: 2197212 DOI: 10.1002/hep.1840120116]

95 **Galoosian A**, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. *J Clin Transl Hepatol* 2020; **8**: 49-60 [PMID: 32274345 DOI: 10.14218/JCTH.2019.00049]

96 **Newton JL**, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. *Hepatology* 2006; **44**: 91-98 [PMID: 16800007 DOI: 10.1002/hep.21230]

97 **Biagini MR**, Tozzi A, Milani S, Grippo A, Amantini A, Capanni M, Galli A, Surrenti C. Fatigue in primary biliary cirrhosis: a possible role of comorbidities. *Eur J Gastroenterol Hepatol* 2008; **20**: 122-126 [PMID: 18188032 DOI: 10.1097/MEG.0b013e3282f1cbda]

98 **Newton JL**. Fatigue in primary biliary cirrhosis. *Clin Liver Dis* 2008; **12**: 367-83; ix [PMID: 18456186 DOI: 10.1016/j.cld.2008.02.010]

99 **Reshetnyak VI,** Maev IV. Mechanism for development of malnutrition in primary biliary cholangitis. *World J Meta-Anal* 2022; **10**: 81-98 [DOI: 10.13105/wjma.v10.i3.81]

100 **Flannery GR**, Burroughs AK, Butler P, Chelliah J, Hamilton-Miller J, Brumfitt W, Baum H. Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens. *Hepatology* 1989; **10**: 370-374 [PMID: 2474482 DOI: 10.1002/hep.1840100321]

101 **Green JH**, Bramley PN, Losowsky MS. Are patients with primary biliary cirrhosis hypermetabolic? A comparison between patients before and after liver transplantation and controls. *Hepatology* 1991; **14**: 464-472 [PMID: 1874491]

102 **Jopson L**, Jones DE. Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management. *Dig Dis* 2015; **33 Suppl 2**: 109-114 [PMID: 26641884 DOI: 10.1159/000440757]

103 **Parikh-Patel A**, Gold EB, Utts J, Worman H, Krivy KE, Gershwin ME. Functional status of patients with primary biliary cirrhosis. *Am J Gastroenterol* 2002; **97**: 2871-2879 [PMID: 12425562 DOI: 10.1111/j.1572-0241.2002.07055.x]

104 **Griffiths L**, Jones DE. Pathogenesis of primary biliary cirrhosis and its fatigue. *Dig Dis* 2014; **32**: 615-625 [PMID: 25034296 DOI: 10.1159/000360515]

105 **Mardones P**, Medina JF, Elferink RP. Activation of cyclic AMP Signaling in Ae2-deficient mouse fibroblasts. *J Biol Chem* 2008; **283**: 12146-12153 [PMID: 18319251 DOI: 10.1074/jbc.M710590200]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 19, 2023

**First decision:** August 5, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Russia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Bredt LC, Brazil; Tsoulfas G, Greece **S-Editor:** Qu XL **L-Editor:** Webster JR **P-Editor:**


**Figure Legends**




**Figure 1 Schematic of bicarbonate secretion by small and large cholangiocytes.** AE2: Chloride/bicarbonate anion exchanger 2; TMEM16A: Transmembrane 16A chloride channels; ATP: Adenosine triphosphate; P2YR: Purinergic receptor family; InsP3: Inositol-1,4,5-trisphosphate; InsP3R3: Inositol-1,4,5-trisphosphate receptor type 3; ER: Endoplasmic reticulum; SR: Secretin receptor; cAMP: Cyclic adenosine monophosphate; Ach: Acetylcholine; CFTR: Cystic fibrosis transmembrane conductance regulator; M3R: Muscarinic acetylcholine M3 receptor; HCO3-: Bicarbonate; Cl-: Chloride; Ca2+: Calcium.



**Figure 2 Mechanism of inositol-1,4,5-trisphosphate receptor type 3 and chloride/carbonate (chloride/bicarbonate) anion exchanger 2 gene expression reduction due to the increase in the amount of micro-RNA 506 and its activity.** InsP3R3: Inositol-1,4,5-trisphosphate receptor type 3; AE2: Chloride/bicarbonate anion exchanger 2; miR-506: Micro-RNA 506; TMEM16A: Transmembrane 16A chloride channels; HCO3-: Bicarbonate; Cl-: Chloride.



**Figure 3 Solubilization of phospholipids and cholesterol from membrane structures by bile acids.** BA: Bile acids.



**Figure 4 Mechanism of anti-mitochondrial antibody formation, development of ductulopenia, weakness, fatigue and malaise in the asymptomatic stage of primary biliary cholangitis: hypothesis.** InsP3R3: Inositol-1,4,5-trisphosphate receptor type 3; AE2: Chloride/bicarbonate anion exchanger 2; PDG: Pyruvate dehydrogenase; ATP: Adenosine triphosphate.